CORRECTION Open Access



Correction: CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Fei Xing¹, Hongli Gao¹, Guanglei Chen¹, Lisha Sun¹, Jiayi Sun¹, Xinbo Qiao¹, Jingi Xue¹ and Caigang Liu^{1*}

Correction: *BMC Microbiol Mol Cancer* **22**, 6 (2023) https://doi.org/10.1186/s12943-023-01716-y

Following publication of the original article [1], the authors reported that they spotted two mistakes in the published version. The two mistakes are, (1) wrong group labels in Fig. 2DD and (2) the orders of image panels in Figure S2C and D were mistaken, the images of wound healing at 0 time point in Supplementary Fig. 2C were highly similar between the shRNA#1 and shRNA#2 groups. In addition, the image of the CMTM6 group at 24 h in Supplementary Fig. 2D was easily misunderstood due to the off-center position of the scratch shown. To ensure its accuracy, they wish to correct these errors by replacing correct images in Figure S2C and D, and rearranging the orders of images in Figure S2C and D as well as correcting the group labels in Fig. 2D. The corrections do not alter the findings and conclusions of the study.

The original article [1] has been corrected.

Published online: 05 January 2024

The online version of the original article can be found at https://doi.org/10.1186/s12943-023-01716-y.

*Correspondence:
Caigang Liu
liucg@sj-hospital.org

Department of Oncology, Innovative Cancer Drug Research and
Engineering Center of Liaoning Province, Cancer Stem Cell and
Translation Medicine Lab, Shengjing Hospital of China Medical University,
Shenyang 110022. China



Reference

 Xing F, Gao H, Chen G, et al. CMTM6 overexpression confers trastuzumab resistance in HER2-positive Breast cancer. Mol Cancer. 2023;22:6. https://doi. org/10.1186/s12943-023-01716-y.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.